Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01442779 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by Texas Tech University Health Sciences Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01442779: Completed Phase 2 study, sponsored by Texas Tech University Health Sciences Center.
NCT01442779 is a Phase 2 study that has completed, run by Texas Tech University Health Sciences Center. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01442779, a Phase 2 study, has completed, sponsored by Texas Tech University Health Sciences Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the possible efficacy of low dose, orally administered interferon alpha in subjects with Idiopathic Pulmonary Fibrosis (IPF).
Primary Outcome
Disease progression was determined by comparing results of the High Resolution Computed Tomography(HRCT) and pulmonary function at one year to the baseline HRCT \& pulmonary function. The same radiologist did the comparsion for all subjects.
Interventions
- DRUG Interferon alpha oral lozenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2000-09 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
What the finished NCT01442779 record still lists
NCT01442779 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Interferon alpha oral lozenge is the first listed.
NCT01442779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01442779 about?
NCT01442779 is a clinical study titled "Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis". The purpose of this study is to determine the possible efficacy of low dose, orally administered interferon alpha in subjects with Idiopathic Pulmonary Fibrosis (IPF).
What is the current status of trial NCT01442779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2000-09. Estimated completion is 2007-05.
What interventions are being tested in trial NCT01442779?
The interventions under investigation include: Interferon alpha oral lozenge (DRUG).
Who is sponsoring clinical trial NCT01442779?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01442779's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia